|
WO2000078735A1
(de)
|
1999-06-21 |
2000-12-28 |
Boehringer Ingelheim Pharma Kg |
Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
|
US7019012B2
(en)
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
|
DE10204462A1
(de)
*
|
2002-02-05 |
2003-08-07 |
Boehringer Ingelheim Pharma |
Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
|
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
|
US20040044014A1
(en)
|
2002-04-19 |
2004-03-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
|
|
DE10221018A1
(de)
*
|
2002-05-11 |
2003-11-27 |
Boehringer Ingelheim Pharma |
Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
|
|
PE20040945A1
(es)
*
|
2003-02-05 |
2004-12-14 |
Warner Lambert Co |
Preparacion de quinazolinas substituidas
|
|
US7223749B2
(en)
|
2003-02-20 |
2007-05-29 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
|
DE10307165A1
(de)
*
|
2003-02-20 |
2004-09-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
|
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
|
DE10334226A1
(de)
*
|
2003-07-28 |
2005-02-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
|
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
|
US7569577B2
(en)
|
2003-09-16 |
2009-08-04 |
Astrazeneca Ab |
Quinazoline derivatives as tyrosine kinase inhibitors
|
|
US7456189B2
(en)
|
2003-09-30 |
2008-11-25 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
|
|
DE10349113A1
(de)
|
2003-10-17 |
2005-05-12 |
Boehringer Ingelheim Pharma |
Verfahren zur Herstellung von Aminocrotonylverbindungen
|
|
ME01267B
(me)
*
|
2004-05-06 |
2013-06-20 |
Warner Lambert Co |
4-fenilaminokinazolin-6-ilamidi
|
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
|
WO2006081741A1
(en)
*
|
2005-02-05 |
2006-08-10 |
Piaoyang Sun |
Quinazoline compounds or their medical salts and preparation and medical usage thereof
|
|
KR100832593B1
(ko)
*
|
2005-11-08 |
2008-05-27 |
한미약품 주식회사 |
신호전달 저해제로서의 퀴나졸린 유도체 및 이의 제조방법
|
|
JP5688877B2
(ja)
*
|
2005-11-11 |
2015-03-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
癌疾患の治療用キナゾリン誘導体
|
|
SI1948180T1
(sl)
|
2005-11-11 |
2013-06-28 |
Boehringer Ingelheim International Gmbh |
Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje
|
|
DK1981863T3
(da)
|
2006-01-26 |
2013-01-02 |
Boehringer Ingelheim Int |
Fremgangsmåde til fremstilling af aminocrotonylaminosubtituerede quinazolinderivater
|
|
SI2068880T1
(sl)
|
2006-09-18 |
2012-08-31 |
Boehringer Ingelheim Int |
Postopek za zdravljenje raka, ki vsebuje mutacije EGFR
|
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
|
EA200901041A1
(ru)
|
2007-02-06 |
2010-02-26 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
|
|
RS52573B
(sr)
|
2008-02-07 |
2013-04-30 |
Boehringer Ingelheim International Gmbh |
Spirociklični heterocikli, lekovi koji sadrže navedeno jedinjenje, njihova primena i postupak za njihovu proizvodnju
|
|
BRPI0912170A2
(pt)
|
2008-05-13 |
2015-10-13 |
Astrazeneca Ab |
composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
|
|
PE20100252A1
(es)
|
2008-06-06 |
2010-04-12 |
Boehringer Ingelheim Int |
Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
|
|
US8426430B2
(en)
|
2008-06-30 |
2013-04-23 |
Hutchison Medipharma Enterprises Limited |
Quinazoline derivatives
|
|
CA2733153C
(en)
|
2008-08-08 |
2016-11-08 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
|
US8507502B2
(en)
|
2008-11-10 |
2013-08-13 |
National Health Research Institutes |
Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
|
|
WO2010081817A1
(en)
|
2009-01-14 |
2010-07-22 |
Boehringer Ingelheim International Gmbh |
Method for treating colorectal cancer
|
|
WO2010130758A1
(en)
*
|
2009-05-14 |
2010-11-18 |
Boehringer Ingelheim International Gmbh |
New combination therapy in treatment of cancer and fibrotic diseases
|
|
EP2429520A1
(en)
|
2009-05-14 |
2012-03-21 |
Boehringer Ingelheim International GmbH |
New combination therapy in treatment of oncological and fibrotic diseases
|
|
JP5963672B2
(ja)
|
2009-07-06 |
2016-08-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｂｉｂｗ２９９２、その塩及びこの活性成分を含む固体医薬製剤の乾燥方法
|
|
EP2509592A1
(en)
|
2009-12-07 |
2012-10-17 |
Boehringer Ingelheim International GmbH |
Bibw 2992 for use in the treatment of triple negative breast cancer
|
|
US8735409B2
(en)
*
|
2009-12-21 |
2014-05-27 |
Qiang Zhang |
Quinazoline derivatives
|
|
US20120107304A1
(en)
|
2010-04-27 |
2012-05-03 |
Boehringer Ingelheim International Gmbh |
Combination therapy in treatment of oncological and fibrotic diseases
|
|
DK2608792T3
(en)
|
2010-08-26 |
2018-01-15 |
Boehringer Ingelheim Int |
PROCEDURES FOR SUBMITTING AN EGFR INHIBITOR.
|
|
US9012464B2
(en)
|
2010-11-25 |
2015-04-21 |
Ratiopharm Gmbh |
Salts and polymorphic forms of Afatinib
|
|
KR20200003933A
(ko)
|
2011-03-04 |
2020-01-10 |
뉴젠 세러퓨틱스 인코포레이티드 |
알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
|
|
US8828391B2
(en)
|
2011-05-17 |
2014-09-09 |
Boehringer Ingelheim International Gmbh |
Method for EGFR directed combination treatment of non-small cell lung cancer
|
|
WO2012155339A1
(zh)
*
|
2011-05-17 |
2012-11-22 |
江苏康缘药业股份有限公司 |
4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
|
|
CN102838590B
(zh)
*
|
2011-06-21 |
2014-07-09 |
苏州迈泰生物技术有限公司 |
氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途
|
|
EP2753616A1
(en)
|
2011-10-06 |
2014-07-16 |
Ratiopharm GmbH |
Crystalline forms of afatinib di-maleate
|
|
CN103073539B
(zh)
*
|
2011-10-26 |
2016-05-11 |
齐鲁制药有限公司 |
4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
|
|
HRP20170226T1
(hr)
|
2012-01-17 |
2017-04-07 |
Astellas Pharma Inc. |
Spoj pirazinkarboksamida
|
|
CN103772380A
(zh)
*
|
2012-10-23 |
2014-05-07 |
杨子娇 |
一类治疗房角狭窄的化合物及其用途
|
|
WO2014118197A1
(en)
|
2013-02-01 |
2014-08-07 |
Boehringer Ingelheim International Gmbh |
Radiolabeled quinazoline derivatives
|
|
HK1213818A1
(zh)
|
2013-04-05 |
2016-07-15 |
勃林格殷格翰国际有限公司 |
依帕列净的治疗用途
|
|
ES2702174T3
(es)
|
2013-04-05 |
2019-02-27 |
Boehringer Ingelheim Int |
Usos terapéuticos de empagliflozina
|
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
CA2812519A1
(en)
|
2013-04-05 |
2014-10-05 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
JP2016520564A
(ja)
|
2013-04-18 |
2016-07-14 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
医薬組成物、治療方法及びその使用
|
|
WO2014180271A1
(zh)
*
|
2013-05-10 |
2014-11-13 |
苏州明锐医药科技有限公司 |
阿法替尼及其中间体的制备方法
|
|
CN103254183B
(zh)
*
|
2013-05-10 |
2015-11-11 |
苏州明锐医药科技有限公司 |
阿法替尼的制备方法
|
|
CN103254182A
(zh)
*
|
2013-05-10 |
2013-08-21 |
苏州明锐医药科技有限公司 |
一种阿法替尼的制备方法
|
|
WO2014183560A1
(zh)
*
|
2013-05-16 |
2014-11-20 |
苏州明锐医药科技有限公司 |
阿法替尼及其中间体的制备方法
|
|
CN103242303B
(zh)
*
|
2013-05-16 |
2015-03-25 |
苏州明锐医药科技有限公司 |
阿法替尼的制备方法
|
|
CN104513229A
(zh)
*
|
2013-09-28 |
2015-04-15 |
正大天晴药业集团股份有限公司 |
喹唑啉衍生物及其制备方法
|
|
CN103755688B
(zh)
*
|
2013-12-24 |
2015-11-18 |
江苏奥赛康药业股份有限公司 |
一种阿法替尼化合物的制备方法
|
|
US9242965B2
(en)
*
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
|
EA031059B1
(ru)
|
2014-01-02 |
2018-11-30 |
Тева Фармасьютикалз Интернэшнл Гмбх |
Кристаллическая форма альфа дималеата афатиниба
|
|
CN105315263B
(zh)
*
|
2014-07-30 |
2018-11-27 |
正大天晴药业集团股份有限公司 |
阿法替尼中间体的合成方法
|
|
EP3023421A1
(en)
|
2014-11-21 |
2016-05-25 |
Sandoz Ag |
Crystalline forms of afatinib dimaleate
|
|
CN105801568B
(zh)
|
2015-01-15 |
2019-07-30 |
杭州普晒医药科技有限公司 |
阿法替尼一马来酸盐晶型及其制备方法和药物组合物
|
|
JP6704422B2
(ja)
|
2015-03-20 |
2020-06-03 |
チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. |
キナゾリン誘導体の塩およびその製造方法
|
|
CN105175400B
(zh)
*
|
2015-09-29 |
2018-04-10 |
河北神威药业有限公司 |
一种阿法替尼中间体的制备方法
|
|
WO2017141271A1
(en)
*
|
2016-02-17 |
2017-08-24 |
Sun Pharmaceutical Industries Ltd. |
Stable pharmaceutical composition of afatinib
|
|
CN106442793B
(zh)
*
|
2016-10-21 |
2019-05-24 |
河北神威药业有限公司 |
一种制备阿法替尼的中间体及其对映异构体的检测方法
|
|
MX2019005435A
(es)
|
2016-11-10 |
2019-07-10 |
Boehringer Ingelheim Int |
Composicion farmaceutica, metodos para tratamiento y sus usos.
|
|
TWI808958B
(zh)
|
2017-01-25 |
2023-07-21 |
美商特普醫葯公司 |
涉及二芳基巨環化合物之組合療法
|
|
JP2021506974A
(ja)
*
|
2017-12-18 |
2021-02-22 |
スターングリーン、インク． |
チロシンキナーゼ阻害剤として有用なピリミジン化合物
|
|
CN110437163A
(zh)
*
|
2018-05-03 |
2019-11-12 |
斯特恩格林公司 |
作为酪氨酸激酶抑制剂的嘧啶类化合物
|
|
CN113382986A
(zh)
|
2018-09-25 |
2021-09-10 |
黑钻治疗公司 |
酪氨酸激酶抑制剂组合物、其制备方法和使用方法
|
|
CN109265449B
(zh)
*
|
2018-11-07 |
2021-11-23 |
沈阳工业大学 |
Egfr和her2双靶点酪氨酸激酶抑制剂及制备方法和用途
|
|
BR112021011894A2
(pt)
|
2018-12-21 |
2021-09-08 |
Daiichi Sankyo Company, Limited |
Composição farmacêutica
|
|
CN109824657A
(zh)
*
|
2019-03-26 |
2019-05-31 |
石药集团中奇制药技术（石家庄）有限公司 |
一种二马来酸阿法替尼新晶型及其制备方法和应用
|
|
CN114787150A
(zh)
|
2019-08-15 |
2022-07-22 |
黑钻治疗公司 |
炔基喹唑啉化合物
|
|
CN110590682A
(zh)
*
|
2019-10-14 |
2019-12-20 |
重庆医科大学 |
一种制备阿法替尼杂质的方法以及制备的杂质
|
|
US20210161897A1
(en)
|
2019-11-12 |
2021-06-03 |
Astrazeneca Ab |
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
AU2021211871A1
(en)
|
2020-01-20 |
2022-09-08 |
Astrazeneca Ab |
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
US20210369709A1
(en)
|
2020-05-27 |
2021-12-02 |
Astrazeneca Ab |
EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
|
|
WO2023051687A1
(zh)
*
|
2021-09-30 |
2023-04-06 |
北京赛特明强医药科技有限公司 |
一种喹唑啉类化合物、组合物及其应用
|
|
IL315848A
(en)
|
2022-03-31 |
2024-11-01 |
Astrazeneca Ab |
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment
|
|
US20240116926A1
(en)
|
2022-04-28 |
2024-04-11 |
Astrazeneca Ab |
Heteroaromatic compounds
|
|
WO2023209090A1
(en)
|
2022-04-28 |
2023-11-02 |
Astrazeneca Ab |
Bicyclic heteroaromatic compounds and their application in the treatment of cancer
|
|
CA3249080A1
(en)
|
2022-04-28 |
2023-11-02 |
Astrazeneca Ab |
Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
|
|
WO2023209088A1
(en)
|
2022-04-28 |
2023-11-02 |
Astrazeneca Ab |
Bicyclic heteroaromatic compounds and their use in the treatment of cancer
|
|
KR20250029133A
(ko)
|
2022-06-27 |
2025-03-04 |
아스트라제네카 아베 |
암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제를 포함하는 조합물
|